OMED Insider Trading Activity and SEC Form 4 Filings
OMED insider trading summary
No open-market insider purchases or sales of OncoMed Pharmaceuticals Inc (OMED) have been reported on SEC Form 4 in the past 12 months.
Latest OMED insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 24, 2018 | Austin Gurney | See Remarks | Sell | $7K (11,117 @ $0.60) |
| Oct 10, 2018 | Austin Gurney | See Remarks | Sell | $2K (1,156 @ $2.01) |
| Oct 10, 2018 | Robert Stagg | SVP, Clinical R&D | Sell | $2K (927 @ $2.01) |
| Oct 10, 2018 | John A. Lewicki | President & CEO | Sell | $2K (1,156 @ $2.01) |
| Oct 10, 2018 | Yvonne Li | See Remarks | Sell | $2K (927 @ $2.02) |
| Oct 10, 2018 | Alicia J. Hager | SVP & General Counsel | Sell | $2K (1,156 @ $2.02) |
| Oct 9, 2018 | Yvonne Li | See Remarks | Sell | $3K (1,229 @ $2.13) |
| Oct 9, 2018 | Austin Gurney | See Remarks | Sell | $4K (1,686 @ $2.13) |
| Oct 9, 2018 | John A. Lewicki | President & CEO | Sell | $5K (2,296 @ $2.13) |
| Oct 9, 2018 | Alicia J. Hager | SVP & General Counsel | Sell | $4K (1,686 @ $2.13) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.